These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 12071783)

  • 1. Use of measures of disproportionality in pharmacovigilance: three Dutch examples.
    Egberts AC; Meyboom RH; van Puijenbroek EP
    Drug Saf; 2002; 25(6):453-8. PubMed ID: 12071783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal detection: historical background.
    Egberts TC
    Drug Saf; 2007; 30(7):607-9. PubMed ID: 17604412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?
    van Puijenbroek EP; Egberts AC; Meyboom RH; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2001; 10(2):135-42. PubMed ID: 11499852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions.
    van Puijenbroek E; Diemont W; van Grootheest K
    Drug Saf; 2003; 26(5):293-301. PubMed ID: 12650632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs.
    van Puijenbroek EP; Egberts AC; Heerdink ER; Leufkens HG
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):733-8. PubMed ID: 11214785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.
    van Puijenbroek EP; Bate A; Leufkens HG; Lindquist M; Orre R; Egberts AC
    Pharmacoepidemiol Drug Saf; 2002; 11(1):3-10. PubMed ID: 11998548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter.
    Sundström A; Hallberg P
    Drug Saf; 2009; 32(5):419-27. PubMed ID: 19419236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions.
    Scholl JHG; van Hunsel FPAM; Hak E; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1283-1289. PubMed ID: 31189217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database.
    Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
    Fundam Clin Pharmacol; 2014 Apr; 28(2):230-5. PubMed ID: 23190210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
    Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
    Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database.
    Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
    Ren Fail; 2014 Aug; 36(7):1166-8. PubMed ID: 24826803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hearing impairment associated with oral terbinafine use: a case series and case/non-case analysis in the Netherlands Pharmacovigilance Centre Lareb database and VigiBase™.
    Scholl JH; van Puijenbroek EP
    Drug Saf; 2012 Aug; 35(8):685-91. PubMed ID: 22762134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods.
    Bastos E; Allen JK; Philip J
    Pharmaceut Med; 2024 Jul; 38(4):321-329. PubMed ID: 39003400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.